Bio-Rad Laboratories carries less short-selling pressure into its November 4 results than any closely correlated name in the life science tools sector. Among peers, Agilent Technologies and Repligen have both sustained measurably higher short interest through 2026. Bio-Rad's own lending market registers zero utilization across every reading taken this year, confirmed by FINRA's…
Key data as of 5 Nov 2026
Bio-Rad Laboratories reports Q3 results on October 29 with essentially no short-selling pressure in evidence, a contrast to several life science peers where borrow demand has been more meaningful. Among the closest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIO.B — free to start on ORTEX.
Sign up for free →Open BIO.B on ORTEX